Volume 26, Number 8—August 2020
Research
Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar
Mwinyi Msellem, Ulrika Morris, Aungpaing Soe, Faiza B. Abbas, Abdul-Wahid Ali, Rory Barnes, Paolo Frumento, Abdullah S. Ali, Andreas Mårtensson, and Anders Björkman
Table 4
Artesunate/amodiaquine treatment outcome with 28-day follow-up for increased sensitivity of Plasmodium falciparum to artesunate/amodiaquine despite 14 years as first-line malaria treatment, Zanzibar
| Year of study, group | No patients* | No. (%) positive on day 3 | No. (%) with parasite recrudescence† | No. (%) with recurrent new infection | p value‡ |
|---|---|---|---|---|---|
| 2002–2003, all patients§ | 206 | 1 (0.5) | 13 (6) | 44 (22) | Referent |
| 2005, all patients§ | 172 | 0 | 7 (4) | 16 (9) | Referent |
| 2017, all patients | 142 | 1 (1) | 0 | 0 | 0.003 |
| 2017, children <5 y of age | 21 | 0 | 0 | 0 | 0.614 |
| 2017, children <10 y of age | 42 | 0 | 0 | 0 | 0.243 |
| 2017, children <15 y of age | 66 | 0 | 0 | 0 | 0.055 |
| 2017, >2,000 parasites/µL | 115 | 0 | 0 | 0 | 0.006 |
*Number fulfilling follow-up as per protocol.
†After PCR correction.
‡p value when compared with 2002–2003 and 2005 combined.
§All patients were ≤5 y of age and had parasite densities >2,000 parasites/µL in 2002–2003 and 2005.
Page created: May 26, 2020
Page updated: July 17, 2020
Page reviewed: July 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.